BusinessUnited States1 sourcesNeutral

Ray Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RTx-015 in Retinitis Pigmentosa

Ray Therapeutics (RayTx), a clinical-stage biopharmaceutical company pioneering optogenetic therapies for those living with retinal degenerative diseases, to...

businesswire.com

via businesswire.com

April 1, 2026 | 12:00 PM UTCUpdated 13h ago

Share Read original

Read the full article at businesswire.com →

Ray Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RTx-015 in Retinitis Pigmentosa

Source Verification

Corroboration Score: 1

This story was independently reported by 1 sources. Click any source to read the original article.

businesswire.com

GNewsUS

Comments

0 comments

Be respectful and constructive.

Loading comments...

Ray Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RTx-015 in Retinitis Pigmentosa

Source Verification

Comments

These are the new features in Waves’ ILLUGEN 2.0 update

Visa launches new AI tools to manage the charge dispute process

Related Articles

Tanfield Reports Wider FY'25 Loss; Revenue Remains Nil

INOVIO Announces Proposed Public Offering

Texas Opens Applications For $350M Advanced Nuclear Fund